Muss H B, Bundy B N, Homesley H D, Wilbanks G
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC.
Invest New Drugs. 1987;5(2):199-202. doi: 10.1007/BF00203546.
Twenty-five evaluable patients with advanced non-squamous carcinoma of the uterine cervix were treated with mitoxantrone 12 mg/m2 every three weeks. All patients had good performance status and measurable disease and only 11 had received prior chemotherapy. One complete and one partial response were noted among 15 patients with no prior chemotherapy while no responses were seen in 11 previously treated patients. The major toxicity was myelosuppression; other toxicity was mild. The median progression-free interval was 2.1 months and median survival 4.3 months. Mitoxantrone displays minimal activity in patients with advanced non-squamous carcinoma of the cervix.
25例晚期子宫颈非鳞状细胞癌可评估患者接受了米托蒽醌治疗，剂量为12mg/m²，每三周一次。所有患者的身体状况良好且疾病可测量，只有11例曾接受过化疗。15例未接受过化疗的患者中有1例完全缓解和1例部分缓解，而11例曾接受过治疗的患者未出现缓解。主要毒性为骨髓抑制；其他毒性较轻。无进展生存期的中位数为2.1个月，中位生存期为4.3个月。米托蒽醌对晚期子宫颈非鳞状细胞癌患者的活性极小。
